These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 17222192)

  • 1. A broad antiviral neutral glycolipid, fattiviracin FV-8, is a membrane fluidity modulator.
    Harada S; Yokomizo K; Monde K; Maeda Y; Yusa K
    Cell Microbiol; 2007 Jan; 9(1):196-203. PubMed ID: 17222192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope.
    Harada S
    Biochem J; 2005 Nov; 392(Pt 1):191-9. PubMed ID: 16053446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral activity of fattiviracin FV-8 against human immunodeficiency virus type 1 (HIV-1).
    Habib ES; Yokomizo K; Nagao K; Harada S; Uyeda M
    Biosci Biotechnol Biochem; 2001 Mar; 65(3):683-5. PubMed ID: 11330690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of membrane fluidity on human immunodeficiency virus type 1 entry.
    Harada S; Yusa K; Monde K; Akaike T; Maeda Y
    Biochem Biophys Res Commun; 2005 Apr; 329(2):480-6. PubMed ID: 15737612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
    Matsuda K; Hattori S; Komizu Y; Kariya R; Ueoka R; Okada S
    Bioorg Med Chem Lett; 2014 May; 24(9):2115-7. PubMed ID: 24704028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies decrease the envelope fluidity of HIV-1.
    Harada S; Monde K; Tanaka Y; Kimura T; Maeda Y; Yusa K
    Virology; 2008 Jan; 370(1):142-50. PubMed ID: 17900650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.
    Jekle A; Chow E; Kopetzki E; Ji C; Yan MJ; Nguyen R; Sankuratri S; Cammack N; Heilek G
    Antiviral Res; 2009 Sep; 83(3):257-66. PubMed ID: 19559732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-deoxy-D-glucose as a potential drug against fusogenic viruses including HIV.
    Parris GE
    Med Hypotheses; 2008; 70(4):776-82. PubMed ID: 17920779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane].
    Sun W; Wang HT; Xia CL; Wu SG; Jiang SB; Jiang ZH; Liu SW
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1127-31. PubMed ID: 18676243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
    Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M
    Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
    Ueoka R; Komizu Y; Matsumoto Y; Zhong Y; Tanaka R; Yamamoto N
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4578-80. PubMed ID: 18672367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
    Ketas TJ; Schader SM; Zurita J; Teo E; Polonis V; Lu M; Klasse PJ; Moore JP
    Virology; 2007 Aug; 364(2):431-40. PubMed ID: 17428517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions.
    Bertaux C; Daelemans D; Meertens L; Cormier EG; Reinus JF; Peumans WJ; Van Damme EJ; Igarashi Y; Oki T; Schols D; Dragic T; Balzarini J
    Virology; 2007 Sep; 366(1):40-50. PubMed ID: 17498767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligonucleotide-mediated retroviral RNase H activation leads to reduced HIV-1 titer in patient-derived plasma.
    Heinrich J; Mathur S; Matskevich AA; Moelling K
    AIDS; 2009 Jan; 23(2):213-21. PubMed ID: 19098491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility to virus-cell fusion at the plasma membrane is reduced through expression of HIV gp41 cytoplasmic domains.
    Malinowsky K; Luksza J; Dittmar MT
    Virology; 2008 Jun; 376(1):69-78. PubMed ID: 18400243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays.
    Heyndrickx L; Vermoesen T; Vereecken K; Kurth J; Coppens S; Aerts L; Ohagen A; Van Herrewege Y; Lewi P; Vanham G
    J Virol Methods; 2008 Mar; 148(1-2):166-73. PubMed ID: 18192031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of glycyrrhizin on the expression of hepatitis B virus and Toll like receptors 2,4 in HepG2.2.15 cells expressing low HBsAg].
    Li YW; Yang HZ; Ke QS; Chen W; Chen XJ
    Zhong Yao Cai; 2008 Mar; 31(3):403-7. PubMed ID: 18619248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.